MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ)
$18.41 0.18 (0.9874%)
Analysed MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) News Sources
MoonLake’s lead asset shows durability in late-stage HS studies
31-03-2026
clinicaltrialsarena.com
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa
05-04-2026
yahoo.com
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
07-04-2026
fool.com
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
18-04-2026
fool.com
Avalo shares spike on skin drug data; BioNTech to cut staff
06-05-2026
biopharmadive.com
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
10-05-2026
yahoo.com
Update: MoonLake Immunotherapeutics Q1 Net Loss Widens
11-05-2026
yahoo.com
MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing
11-05-2026
advfn.com
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
11-05-2026
yahoo.com
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway
12-05-2026
yahoo.com
What is the current price of MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ)?
The current price of MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) is $18.41.
MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) since the previous trading day is $0.18.
MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) since the previous trading day is 0.9874%.
What is the most recent average sentiment score for MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ)?
The most recent average sentiment score for MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) is 55 out of 100.
What is the most recent average sentiment for MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ)?
The most recent sentiment for MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ) is .
SEC-8K** Filing Available For MOONLAKE IMMUNOTHERAPEUTICS (MLTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.